SIETES :: 93008 citas

Resultados de la búsqueda por Avorn,J REFINAR BÚSQUEDA

1.

Avorn J. The psychology of clinical decision making — Implications for medication use. N Engl J Med 2018;378:22 de febrero. [Ref.ID 102556]

2.

Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

3.

Fralick M, Avorn J, Kesselheim AS. The price of crossing the border for medications. N Engl J Med 2017;377:311-3. [Ref.ID 101925]

4.

Kesselheim AS, Donneyong M, Dal Pan GJ, Zhou EH, Avorn J, Schneeweiss S, Seeger JD. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf 2017;26:712-21. [Ref.ID 101627]

5.

Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA 2016;316:858-71. [Ref.ID 100589]

6.

Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim S. Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts. JAMA Intern Med 2016;176:junio. [Ref.ID 100237]

7.

Avorn J, Sarpatwari A, Kesselheim AS. Forbidden and permitted statements about medications - Loosening the rules. N Engl J Med 2015;373:967-73. [Ref.ID 99432]

8.

Sarpatwari A, Avorn J, Kesselheim AS. Progress and hurdles for follow-on biologics. N Engl J Med 2015;372:2380-2. [Ref.ID 99297]

9.

Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J. Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf 2015;38:565-75. [Ref.ID 99239]

10.

Avorn J. The $2.6 billion pill — Methodologic and policy considerations. N Engl J Med 2015;372:1877-9. [Ref.ID 99114]

11.

Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407-19. [Ref.ID 98960]

12.

Bateman BT, Hernández-Díaz S, Fischer MA, Seely EW, Ecker JL, Franklin JM, Desai RJ, Allen-Coleman C, Mogun H, Avorn J, Huybrechts KF. Statins and congenital malformations: cohort study. BMJ 2015;350:h1035. [Ref.ID 98870]

13.

Kesselheim AS, Bykov K, Avorn J, Tong A, Doherty M, Choudhry NK. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case - control studies. Ann Intern Med 2014;161:96-103. [Ref.ID 97814]

14.

Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, Mogun H, Levin R, Kowal M, Setoguchi S, Hernández-Díaz S. Antidepressant use in pregnancy and risk of cardiac defects. N Engl J Med 2014;370:2397-407. [Ref.ID 97770]

15.

Gagne JJ, Bykov K, Choudhry NK, Toomey TJ, Connolly JG, Avorn J. Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ 2013;347:11. [Ref.ID 96346]

16.

Avorn J. Healing the overwhelmed physician. N Y Times (Print) 2013:11 de junio. [Ref.ID 95635]

17.

Avorn J. Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA 2013;309:1349-50. [Ref.ID 95234]

18.

Kesselheim AS, Misono AS, Shrank WH, Greene JA, Doherty M, Avorn J, Choudhry NK. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med 2013;173:202-8. [Ref.ID 94940]

19.

Kesselheim AS, Mello MM, Avorn J. FDA regulation of off-label drug promotion under attack. JAMA 2013;309:445-6. [Ref.ID 94907]

20.

Kesselheim AS, Avorn J, Greene JA. Risk, responsibility, and generic drugs. N Engl J Med 2012;367:1679-81. [Ref.ID 93957]